Quoin Pharmaceuticals, Ltd. - American Depositary Shares, each representing Thirty-five (35) Ordinary Shares, no par value per share (QNRX)
CUSIP: 74907L409
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / American Depositary Shares, each representing Thirty-five (35) Ordinary Shares, no par value per share
- Shares outstanding
- 1,802,885
- Total 13F shares
- 2,537
- Share change
- +2,429
- Total reported value
- $23,400
- Price per share
- $9.23
- Number of holders
- 6
- Value change
- +$22,428
- Number of buys
- 5
- Number of sells
- 1
Quarterly Holders Quick Answers
What is CUSIP 74907L409?
CUSIP 74907L409 identifies QNRX - Quoin Pharmaceuticals, Ltd. - American Depositary Shares, each representing Thirty-five (35) Ordinary Shares, no par value per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 74907L409:
Top shareholders of QNRX - Quoin Pharmaceuticals, Ltd. - American Depositary Shares, each representing Thirty-five (35) Ordinary Shares, no par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC |
13D/G
|
— |
5%
|
1,081,183
|
$7,049,313 | $0 | 31 Mar 2025 | |
| Denise P. Carter |
13D/G
|
Denise Carter |
4.9%
|
939,238
|
$244,202 | +$82,374 | 27 Jan 2025 | |
| Michael Myers |
13D/G
|
— |
4.9%
|
939,230
|
$244,200 | +$82,331 | 27 Jan 2025 | |
| Gordon Dunn |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
734,513
mixed-class rows
|
$67,985 | — | 23 Dec 2024 | |
| UBS Group AG |
13F
|
Company |
2.3%
|
219,295
|
$49,122 | — | 31 Mar 2025 | |
| Apollon Wealth Management, LLC |
13F
|
Company |
0.86%
|
80,025
|
$17,918 | — | 31 Mar 2025 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.45%
|
41,741
|
$9,554 | — | 31 Mar 2025 | |
| RAYMOND JAMES FINANCIAL INC |
13F
|
Company |
0.27%
|
25,119
|
$5,624 | — | 31 Mar 2025 | |
| Lido Advisors, LLC |
13F
|
Company |
0.25%
|
23,515
|
$5,265 | — | 31 Mar 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.12%
|
11,210
|
$2,569 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0%
|
456
|
$102 | — | 31 Mar 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
144
|
$33 | — | 31 Mar 2025 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0.01%
|
108
|
$24 | — | 31 Mar 2025 | |
| Raiffeisen Bank International AG |
13F
|
Company |
0%
|
17
|
$4 | — | 31 Mar 2025 |
Institutional Holders of Quoin Pharmaceuticals, Ltd. - American Depositary Shares, each representing Thirty-five (35) Ordinary Shares, no par value per share (QNRX) as of Q2 2025
As of 30 Jun 2025,
Quoin Pharmaceuticals, Ltd. - American Depositary Shares, each representing Thirty-five (35) Ordinary Shares, no par value per share (QNRX) was held by
6 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
2,537 shares.
The largest 6 holders included
RHUMBLINE ADVISERS, RAYMOND JAMES FINANCIAL INC, GAMMA Investing LLC, MORGAN STANLEY, UBS Group AG, and SBI Securities Co., Ltd..
This page lists
6
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
1
Q2 2025 holders
6
Holder diff
5
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.